Posted On: 12/27/2014 10:46:53 AM
Post# of 30066
LYMPRO launched AMBS pps in July, it will repeat the launch in January I believe. One fact is certain, LYMPRO has the attention of everyone:
1) Investors....we saw the interest in July, and the anticipation exploded the pps to a new high .19
2) Bashers, who understand the magnitude and significance of LYMPRO for the BP clinical trials, and then the general public at large
so they continue to bash the stock trying desperately to drive down the pps to buy more. This group understands well that
the commercial launch of LYMPRO to the RUO BP market on Dec. 22 2014 which will initiate revenues this quarter and beyond
3)BP and perhaps hedge funds because Amarantus expects to announce the full results of its in-depth analysis of the full mild-to-severe AD cohort of 140 subjects (initial 72 patients + 68 patient extension) by year-end 2014, and make a final determination on which assay conditions (Version 1 vs. Version 2) it will use to support its product launch. CLIA launch will follow with a potential 3 Billion Mkt...
Yes, LYMPRO will launch AMBS just like it did before, but this time will have the supporting data. I do believe along with everyone else, including the "serial bashers" that LYMPRO will launch AMBS pps in 2015. Don't be deceived by the constant bashing of a few who have a clear agenda. Buckle up and prepared for an epic ride in 2015 and beyond I believe. Do your own DD and tune out the white noise!
1) Investors....we saw the interest in July, and the anticipation exploded the pps to a new high .19
2) Bashers, who understand the magnitude and significance of LYMPRO for the BP clinical trials, and then the general public at large
so they continue to bash the stock trying desperately to drive down the pps to buy more. This group understands well that
the commercial launch of LYMPRO to the RUO BP market on Dec. 22 2014 which will initiate revenues this quarter and beyond
3)BP and perhaps hedge funds because Amarantus expects to announce the full results of its in-depth analysis of the full mild-to-severe AD cohort of 140 subjects (initial 72 patients + 68 patient extension) by year-end 2014, and make a final determination on which assay conditions (Version 1 vs. Version 2) it will use to support its product launch. CLIA launch will follow with a potential 3 Billion Mkt...
Yes, LYMPRO will launch AMBS just like it did before, but this time will have the supporting data. I do believe along with everyone else, including the "serial bashers" that LYMPRO will launch AMBS pps in 2015. Don't be deceived by the constant bashing of a few who have a clear agenda. Buckle up and prepared for an epic ride in 2015 and beyond I believe. Do your own DD and tune out the white noise!
(0)
(0)
